Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Surrozen, Inc./DE

Get SEC filing alerts via email and in your feed for Surrozen, Inc./DE

SRZN SRZNW

Surrozen, Inc./DE

About Surrozen, Inc./DE

Surrozen is a biotechnology company focused on discovering and developing biologic therapeutics that selectively modulate the Wnt signaling pathway to promote tissue repair and regeneration. Its core platform uses proprietary antibody technologies, including Wnt mimetics, to target diseases across multiple organs, with a primary emphasis on ophthalmology. The company aims to address unmet medical needs in severe diseases such as retinal disorders, corneal dystrophies, and tissue injuries through innovative, tissue-specific Wnt pathway activation.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Surrozen, Inc./DE

1
1
Surrozen, Inc./DE Surrozen Reports $5M Revenue Growth and $127.5M Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Surrozen, Inc./DE Surrozen, Inc. Reports Fiscal Year 2025 Results with Focus on Ophthalmology

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Surrozen, Inc./DE Surrozen Reports 90% Revenue Decline and $71.64 Million Net Loss in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Surrozen, Inc./DE Surrozen Reports $39.7 Million Net Income Turnaround in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Surrozen, Inc./DE Surrozen Reports Increased Losses of $26.97 Million in Q1 2025, Completes $71.3 Million PIPE

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Surrozen, Inc./DE Surrozen Reports $63.6 Million Net Loss for 2024, Despite Revenue Growth to $10.65 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Surrozen, Inc./DE Surrozen, Inc. Reports Improved Financials, Net Loss, and Strategic Changes in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments